Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
Exact Sciences: Q3 Sell-Off May Be Unjustified, But Long-Term Outlook A Concern
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
Exact Sciences股票目标价下调，但维持优于大盘评级，原因是收入前景
周三，贝尔德(Baird)维持了对Exact Sciences(NASDAQ:EXAS)股票的优于大盘评级，但将其目标价从70.00美元下调至67.00美元。这一调整是在该公司报告第三季度收入低于预期并大幅下调2024年收入指引之后做出的。下调主要是由于筛查业务趋势弱于预期。 Exact Sciences在8月至10月期间经历了Cologuard产品的异常订单模式，加上商业执行挑战、飓风影响以及销 ...
Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international ...
Exact Sciences Third Quarter 2024 Earnings: Misses Expectations
Third Quarter 2024 Results Key Financial Results Revenue: US$708.7m (up 13% from ...
Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other ...
U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday. Shares of Exact ...
Exact Sciences Poised for Recovery and Long-Term Growth Amidst Challenges
Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...
Investor's Business Daily on MSN5 天
Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook
Exact Sciences stock tumbled late Tuesday after the company cut its outlook and posted weaker-than-expected results.Shares of ...
Canaccord Genuity看好Exact Sciences股票潜力，上调目标价
周二，Canaccord Genuity维持对Exact Sciences Corporation (NASDAQ:EXAS)的买入评级，并将该股票的目标价从此前的$75上调至$95。该公司分析师强调了Exact Sciences的Cologuard业务的强劲势头，指出该产品从2021年到2023年的年复合增长率 (CAGR)约为31%。
bovnews3 天
What’s Behind the -23.48% Drop in Exact Sciences Corp (EXAS) Stock? Find Out Now!
On Wednesday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $54.72 which represents a decrease of $-16.79 or -23.48% from the prior close of $71.51. The stock opened at $55.7 and ...
Business Insider4 天
Exact Sciences price target lowered to $70 from $75 at Wells Fargo
Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Exact Sciences (EXAS) to $70 from $75 and keeps an Overweight rating on the shares. The firm notes Exact Sciences reported a ...
Exact Sciences Stock Falls After Cutting Outlook, Posting Lower-Than-Expected 3Q Results
Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.